Ligand Pharmaceuticals Incorporated (LGND)

Portfolio

Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.

Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.

Ligand has multiple technologies and unpartnered programs available for out-licensing.

View Investor Relations Latest Corporate Presentation

Dec 6, 2023 • 4:02 PM EST

Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City

Nov 8, 2023 • 4:01 PM EST

Ligand Reports Third Quarter 2023 Financial Results

Nov 1, 2023 • 8:00 AM EDT

Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million

LGND

Nasdaq

Volume

Market Cap

Day Range

52-Week Range